2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2005070698v1 17/3/707    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thurman, J. M. Articles by Holers, V. M. Search for Related Content PubMed PubMed Citation Articles by Thurman, J. M. Articles by Holers, V. M.

Treatment with an Inhibitory Monoclonal Antibody to Mouse Factor B Protects Mice from Induction of Apoptosis and Renal Ischemia/Reperfusion Injury

Joshua M. Thurman^*, Pamela A. Royer^*, Danica Ljubanovic, Belda Dursun^*, Amanda M. Lenderink^*, Charles L. Edelstein^* and V. Michael Holers^*

^* Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado; and Department of Pathology, University Hospital Dubrava, Zagreb, Croatia

Address correspondence to: Dr. Joshua M. Thurman, University of Colorado Health Sciences Center, Division of Renal Diseases and Hypertension, 4200 E. 9th Avenue, B-115, Denver, CO 80262. Phone: 303-315-0171; Fax: 303-315-5540; joshua.thurman{at}uchsc.edu

Received for publication July 8, 2005. Accepted for publication December 10, 2005.

Complement activation in the kidney after ischemia/reperfusion (I/R) seems to occur primarily via the alternative complement pathway. The ability of an inhibitory mAb to mouse factor B, a necessary component of the alternative pathway, to protect mice from ischemic acute renal failure was tested. Treatment with the mAb prevented the deposition of C3b on the tubular epithelium and the generation of systemic C3a after renal I/R. Treated mice had significantly lower increases in serum urea nitrogen and developed significantly less morphologic injury of the kidney after I/R. For gaining insight into potential mechanisms of protection, the activity of caspases within the kidney also was measured, and it was found that caspases-2, -3, and -9 increased in a complement-dependent manner after renal I/R. Apoptotic cells were detected by terminal deoxynucleotidyl transferase catalyzed labeling of DNA fragments, and mice in which the alternative pathway was inhibited demonstrated significantly less apoptosis than control mice. Thus, use of an inhibitory mAb to mouse factor B effectively prevented activation of complement in the kidney after I/R and protected the mice from necrotic and apoptotic injury of the tubules.

This article has been cited by other articles:

				N. K. Banda, B. Levitt, M. J. Glogowska, J. M. Thurman, K. Takahashi, G. L. Stahl, S. Tomlinson, W. P. Arend, and V. M. Holers Targeted Inhibition of the Complement Alternative Pathway with Complement Receptor 2 and Factor H Attenuates Collagen Antibody-Induced Arthritis in Mice J. Immunol., November 1, 2009; 183(9): 5928 - 5937. [Abstract] [Full Text] [PDF]

				M. Naesens, L. Li, L. Ying, P. Sansanwal, T. K. Sigdel, S.-C. Hsieh, N. Kambham, E. Lerut, O. Salvatierra, A. J. Butte, et al. Expression of Complement Components Differs Between Kidney Allografts from Living and Deceased Donors J. Am. Soc. Nephrol., August 1, 2009; 20(8): 1839 - 1851. [Abstract] [Full Text] [PDF]

				X. Zheng, X. Zhang, B. Feng, H. Sun, M. Suzuki, T. Ichim, N. Kubo, A. Wong, L. R. Min, M. E. Budohn, et al. Gene Silencing of Complement C5a Receptor Using siRNA for Preventing Ischemia/Reperfusion Injury Am. J. Pathol., October 1, 2008; 173(4): 973 - 980. [Abstract] [Full Text] [PDF]

				A. M. Lenderink, K. Liegel, D. Ljubanovic, K. E. Coleman, G. S. Gilkeson, V. M. Holers, and J. M. Thurman The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy Am J Physiol Renal Physiol, August 1, 2007; 293(2): F555 - F564. [Abstract] [Full Text] [PDF]

				L. Bao, Y. Wang, A. Chang, A. W. Minto, J. Zhou, H. Kang, M. Haas, and R. J. Quigg Unrestricted C3 Activation Occurs in Crry-Deficient Kidneys and Rapidly Leads to Chronic Renal Failure J. Am. Soc. Nephrol., March 1, 2007; 18(3): 811 - 822. [Abstract] [Full Text] [PDF]

				J. M. Thurman, A. M. Lenderink, P. A. Royer, K. E. Coleman, J. Zhou, J. D. Lambris, R. A. Nemenoff, R. J. Quigg, and V. M. Holers C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion J. Immunol., February 1, 2007; 178(3): 1819 - 1828. [Abstract] [Full Text] [PDF]

				D. Spitzer, X. Wu, X. Ma, L. Xu, K. P. Ponder, and J. P. Atkinson Cutting Edge: Treatment of Complement Regulatory Protein Deficiency by Retroviral In Vivo Gene Therapy J. Immunol., October 15, 2006; 177(8): 4953 - 4956. [Abstract] [Full Text] [PDF]

				M. Nangaku A Crry for polar shedding Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1773 - 1775. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673